Recent Highlights
All Stories for Gilead
WHO advises against use of Remdesivir to treat COVID-19, says drug has no 'important effect' to reduce deaths
• 4 years agoA WHO Guideline Development Group of international experts said there was 'no evidence based on currently available data that the anti-viral drug does improve patient-important outcomes'
Mylan's remdesivir to cost Rs 4,800 per 100 mg vial in India, 80% cheaper than price tag in wealthy nations
• 5 years agoGilead priced remdesivir at $2,340 per patient for rich nations and agreed to send nearly all of its supply of the drug to the United States over the next three months
Coronavirus Outbreak: Gilead Sciences says supply of Remdesivir to exceed 20 lakh by end of the year
• 5 years agoGilead Sciences Inc expects supply of its potential COVID-19 drug Remdesivir to exceed twenty lakh courses by year-end, the company said on Monday, more than double its previous target of 10 lakh.
Hetero gets DCGI nod to launch anti-viral drug Remdesivir under brand name Covifor for COVID-19 treatment
• 5 years agoThe drug has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children, hospitalised with severe symptoms of the disease, the company said.
FDA warns against the usage of Remdesivir along with malaria antiviral hydroxychloroquine
• 5 years agoFDA said it was no longer reasonable to believe that oral formulations of HCQ maybe effective in treating the illness caused by COVID-19.
Gilead's Remdesivir prevented lung disease in macaque monkeys infected with coronavirus: Study
• 5 years agoThe antiviral drug, Remdesivir is the first drug shown to be effective against COVID-19 in human trials.
Gilead granted marketing authorisation for remdesivir for potential Covid-19 treatment in India
• 5 years agoIndia has allowed adults and children who have been hospitalised with severe COVID-19 symptoms to be treated with Remdesivir
Remdesivir improved symptoms when administered to moderately ill COVID-19 patients: Gilead
Tech2 News Staff • 5 years agoThe administration of this drug will be given to patients who show signs of a sever COVID-19 infection for a period of five days as well.
Coronavirus India Update, May 14: Cases cross 78,000, Goa no longer a Green Zone, India to test 4 drugs for WHO trials
Myupchar • 5 years agoThe total number of COVID-19 cases in India has reached 78,003, with the death toll surging to 2,549. The current number of active cases is 49,219.
Jubilant Life Sciences shares jump 5% after company signs pact with Gilead COVID-19 therapy drug
• 5 years agoShares of Jubilant Life Sciences on Wednesday rose 5 percent after the company said it has entered into a pact with Gilead Sciences for an investigational drug, remdesivir which is a potential therapy for COVID-19